... of the involvement of the axilla is important because of the prognostic importance of lymph node metastases. After neoadjuvant chemotherapy (NACT), targeted axillary dissection (TAD), including sentinel lymph node biopsy and primarily involved lymph nodes, is currently regarded as the standard of care. The target...

... blue dye (MBD) and factors which can lead to a false negative rate (FNR) threshold of 10%. Methods: This was a prospective cross-sectional non-randomized validation study in patients with post-neoadjuvant chemotherapy (NACT) clinically node negative axilla who were node positive prior to start of NACT...

...Michael Patrick Lux; Christof Minartz; Harald Müller-Huesmann; Marianar Felicia Sandor; Sabine Radeck-Knorre; Aljoscha Steffen Neubauer Background: Gene expression tests can inform decisions on whether to recommend or omit chemotherapy for patients with early HR+, HER2− breast cancer. The benefit...

...Roman Vion; Patricia Fleury; Valérie Blazejewski; Olivier Rigal; Maxime Fontanilles; Justine Lequesne; Frederic Di Fiore; Florian Clatot Background: The presence of a breast nurse is recommended to advise and guide early breast cancer patients before and during chemotherapy/radiation therapy...

...Marcus Schmidt Background: Chemotherapy, used either before or after surgery, has significantly improved survival in early breast cancer. Accurate risk assessment is essential to avoid both overtreatment and undertreatment. This review provides an overview of the evolution of chemotherapy as well...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Chemotherapy Metastatic breast cancer Objective response Survival...

... from any ideas, methods, instructions or products referred to in the content or advertisements. 2021 Early breast cancer Neoadjuvant systemic therapy Adjuvant treatment Endocrine therapy Chemotherapy Breast surgery Axillary surgery Radiotherapy Immunotherapy Survivorship Consensus...

...Rosalba Torrisi; Vera Basilico; Laura Giordano; Michele Caruso; Antonino Musolino; Marta Noemi Monari; Carlo Carnaghi; Armando Santoro Introduction: Anti-Müllerian hormone (AMH) is the most reliable biomarker of ovarian reserve; however, its role in predicting ovarian recovery after chemotherapy...

... anthracycline-based chemotherapy. To determine its prognostic versus predictive value, the impact of PITX2 DNA methylation on outcomes was studied in an untreated cohort vs. an anthracycline-treated triple-negative breast cancer (TNBC) cohort. Material and Methods: The percent DNA methylation ratio (PMR...

... breast cancer patients without adjuvant systemic therapy. In the present study we evaluated the prognostic significance of IGKC in breast cancer patients treated with adjuvant chemotherapy ± tamoxifen. Methods: IGKC expression was immunohistochemically analyzed in 193 breast cancer patients who were...

... on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy. Methods: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients. Results: Cumulative incidence rates of motor...

.... Kates; Monika Karla Graeser Background: Protroca evaluated the efficacy and safety of primary and secondary prophylaxis of neutropenia with lipegfilgrastim (Lonquex®) in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy (CT). Patients and Methods: Of the 255 patients enrolled, 248...

... of Oncology . Early breast cancer Neoadjuvant systemic therapy Adjuvant treatment Endocrine therapy Chemotherapy Bisphosphonates Denosumab Breast surgery Sentinel node Axillary dissection Radiotherapy Targeted therapy The St. Gallen Consensus Conference 2019 (March 20–23) was held...

... patients who had been diagnosed with primary breast cancer at least 1 year before. Results: Fatigue, depression, depressive mood, concentration deficit, pain, changes of mucosa and skin appendages, as well as symptoms of peripheral neuropathy were the most prevalent reported complaints. Chemotherapies...

... options, dermatologic side effects are also becoming increasingly complex and more challenging for the clinician. We reviewed the most common dermatologic side effects of current anticancer therapy, including toxicity induced by chemotherapy, targeted therapy, and immunotherapy. In particular, we focus...

... cancer, allowing patient-specific benefit of chemotherapy to be evaluated. Our aim was to determine whether the introduction of Oncotype DX led to a net reduction in chemotherapy use. Methods: Consecutive patients that underwent Oncotype DX at Warwick Hospital were reviewed. Patients were anonymised...

...Fernando Kude de Almeida; Daniela Dornelles Rosa Summary Adjuvant chemotherapy has greatly improved the prognosis of early breast cancer. Dose-dense chemotherapy seeks to increase efficacy by changing the interval between cycles of treatment without the need of increasing doses and toxicity...

...Slavomir Krajnak; Marco Battista; Walburgis Brenner; Katrin Almstedt; Tania Elger; Anne-Sophie Heimes; Annette Hasenburg; Marcus Schmidt Summary Background: Low-dose metronomic chemotherapy (LDMC) is increasingly used in metastatic breast cancer (MBC). In this retrospective analysis, we examined...

...Santiago Escrivá-de-Romaní; Miriam Arumí; Esther Zamora; Meritxell Bellet Summary For decades, the neoadjuvant setting has provided a useful scenario for research in breast cancer. Historically, neoadjuvant clinical trials, either hormone therapy-based or chemotherapy-based, have tried...

... received adjuvant chemotherapy (6 courses of CAF: cyclophosphamide, doxorubicin, and 5-fluorouracil), radiation, and tamoxifen. The patient has remained disease-free for over 2 years. Conclusion: This study demonstrates that triple-positive MPC of the male breast as a rare malignancy appears to respond...